Vedolizumab (VDZ) is an effective treatment for inflammatory bowel disease in both adults and children (IBD). Clinical results, on the other hand, have been found to be superior in individuals who have never had anti-tumor necrosis factor therapy (TNF). With an increased interest in endoscopic endpoints, we sought to report rates of mucosal healing in pediatric patients receiving VDZ and investigate the impact of anti-TNF on outcomes. Researchers performed a retrospective evaluation of all IBD patients over the age of 21 who started VDZ and underwent endoscopy. Mucosal healing and histological remission were the primary outcomes. The data were summarized using descriptive statistics. Univariate testing was used to make comparisons for endpoints depending on anti-TNF exposure. The final study comprised 68 individuals, 35 of whom had UC and 33 of whom had CD. Thirty-two individuals were anti-TNF naive, whereas 36 were anti-TNF exposed. The median time on VDZ prior to endoscopic evaluation was 49 weeks. A total of 38% of patients achieved the primary objective of mucosal healing, with no difference between anti-TNF-naive and anti-TNF-exposed individuals. Endoscopic remission was reached by 51% of patients, with substantially more anti-TNF naive individuals achieving this goal. 42 percent of patients obtained histologic remission, with a nonsignificant trend toward better histologic remission rates in anti-TNF-naive patients.

In paediatric IBD, VDZ is linked to mucosal repair. Anti-TNF treatment had a substantial influence on endoscopic remission but not histologic remission in children using VDZ.